Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
Ajouter des filtres








Gamme d'année
1.
China Pharmacy ; (12): 3690-3692, 2015.
Article Dans Chinois | WPRIM | ID: wpr-502635

Résumé

OBJECTIVE:To observe clinical effect and safety of temozolomide (TMZ) combined with radiotherapy in the treatment of malignant glioma. METHODS:58 patients with malignant glioma were randomly divided into TMZ-RT group(32 cas-es)and RT group(26 cases). RT group were given the therapy of 3D-CRT 1.8-3 Gy/d,and some patients received the hyperfrac-tion radiotherapy with total dose of 60-75 Gy. TMZ-RT group were given TMZ chemotherapy 75 mg/(m2·d)combined with radio-therapy for 6 weeks and TMZ sequential therapy 150-200 mg/(m2·d)for 4 weeks. Therapeutic efficacy and ADR were observed in 2 groups. RESULTS:After treatment,in TMZ-RT group,9 cases had complete remission,11 cases had partial remission,10 cas-es were stable and 2 cases were progressive;in RT group,6 cases had complete remission,8 cases had partial remission,8 cases were stable and 4 cases were progressive. There was no statistical significance in short-term efficacy between 2 groups(P>0.05). The 1,2,3-year survival rates of TMZ-RT group were 81.3%(26/32),78.1%(25/32) and 62.5%(20/32),while those of RT group were 84.6%(22/26),34.6%(9/26)and 15.4%(4/26). There were statistical significance in 2,3-year survival rates between 2 groups (P<0.05). Median recurrent time of TMZ-RT group was (23.2 ± 8.6) months,while that of RT group was (15.6 ± 8.7) months,with statistical significance(P<0.05). According to the KPS,TMZ-RT group was(89.6±9.6)and RT group(65.1±10.1), with statistical significance (P<0.01). The side effect of 2 groups were slight. CONCLUSIONS:Radiotherapy combined with TMZ can significantly improve the survival rates of 2 and 3-year and delay the tumor recurrent time,and lighter adverse reaction. It can be used as new therapy method for malignant glioma. But it needs further study for treating the malignant glioma patients with osteomyelitis or low immune function.

2.
Cancer Research and Clinic ; (6): 457-459, 2012.
Article Dans Chinois | WPRIM | ID: wpr-429141

Résumé

ObjectiveTo evaluate the efficacy and toxicity of 3D-radiotherapy combined with salvia miltiorrhiza injection to treat esophageal cancer. Methods62 patients were randomly divided into group A and B.Group A were treated with 3D-radiotherapy (60-70 Gy) combined with salvia miltiorrhiza injection (20 ml/d).Group B were treated with 3D-radiotherapy (60-70 Gy) combined with cisplatin (30 mg/m2,d1-d3/w).ResultsThe 71.0 %(22/31 ) recent effective rate of group A was obtained[74.2 %(22/31) of group B],the 2 to 3 years survival rates were 66.7 % and 43.3 % respectively(55.3 % and 16.7 % of group B). Conclusion The effect is good using 3D-radiotherapy combined with salvia miltiorrhiza injection to treat esophageal cancer.

3.
Innovation ; : 43-48, 2009.
Article Dans Anglais | WPRIM | ID: wpr-631199

Résumé

PURPOSE To determine the advantages of three-dimensional contormal radiotherapy (3D- CRT) method and to introduce this novel approach of radiotherapy services in Mongolia METHODS 20 patients with different kinds of cancer were randomly evaluated who did 3D CRT clinical treatment planning by using CT-simulator "Siemens Somatom Emotion-6" in Radiotherapy Department of National Cancer C enter of Mongolia. At first, we calculated the gross tumor volume (GTV) and planning target volume (P1 V ) by cm5 in 3D and 2D ways in all patients, then analyzed the volume ot the surrounding tissue based on difference of treated volume and gross tumor volume (Vd%). RESULTS The mean age was 47.5 (range, 3-74); 8 patients (40%) were male. The PTV volume significantly decreased for 3D-CRI plans compared to 2D as indicated by Vd% (average 46.6 vs. 26.7) and treated volume (TV). CONCLUSIONS 3D-CRT is a safe and effective method in patients with cancer who were indicated the radiotherapy. Furthermore, this novel treatment method could potentially benefit from treatment and improve overall survival (OS) and disease-free survival (DFS) in patients with cancer.

SÉLECTION CITATIONS
Détails de la recherche